Advancing Clinical Development of the Drug Discovery Pipeline and External Partnerships
First written in FY2017. 7 of 9 entries say "Advanced", first in FY2018. Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 7 companies on the "Worse" side.
6 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In particular, the joint research with 株式会社三和化学研究所 successfully produced a treatment candidate compound, SK-2407/SN-001, for dentatorubral-pallidoluysian atrophy, and the two companies are advancing domestic development.」
Nucleic acid drug discovery has advanced to the stage of successfully producing a candidate compound and pursuing domestic development with 三和化学研究所. Collaboration with ADDP on drug discovery support and DEL technology has also begun. - FY2025AdvancedAnnual report
「In drug discovery, the company signed a licensing agreement with マルホ株式会社 in 2024 for a novel pain treatment candidate compound and will advance joint development going forward.」
A licensing agreement was signed with マルホ株式会社 for a novel pain treatment candidate compound, advancing the project to the joint development stage. In nucleic acid drug discovery, the company also reported the successful selection of a development compound with 三和化学研究所 and domestic joint development. - FY2024AdvancedAnnual report
「In the joint research on antisense nucleic acid drug discovery conducted with 株式会社三和化学研究所 since 2019, the company successfully selected a development candidate and newly signed a comprehensive partnership agreement. The two companies will strategically pursue the creation of multiple novel nucleic acid medicines.」
The joint research with 三和化学研究所 successfully produced a development candidate, and a comprehensive partnership agreement was signed. Joint research and partnerships in nucleic acid drug discovery are being expanded to multiple pharmaceutical companies and academic institutions. - FY2023AdvancedAnnual report
「Joint research on the company's proprietary drug discovery platform technology using its original nucleic acid structures is progressing smoothly with several pharmaceutical companies. Multiple projects launched in 2019 have advanced to the stage of progressing their respective themes, expanding the company's partnerships.」
The company has reported progress in multiple nucleic acid drug discovery projects, joint research with pharmaceutical companies and academia, and expanded partnerships. For NTC-801, it continues to assess development potential after completion of the investigator-initiated clinical trial and consider potential partners. - FY2022AdvancedAnnual report
「NTC-801, an antiarrhythmic drug, was selected for the Innovative Medical Seeds Practical Application Research Program operated by the Japan Agency for Medical Research and Development (AMED), and the investigator-initiated clinical trial at Osaka University, the joint research partner, in patients with hereditary bradyarrhythmia was completed. The company will continue considering potential partners based on the trial results.」
Separately from the discontinuation of NIP-022, NTC-801 completed its investigator-initiated clinical trial and has advanced to the stage of considering potential partners based on the trial results. - FY2021DroppedAnnual report
「Following a business feasibility assessment of the expected indications for NIP-022, a platelet-increasing drug, in Japan and Asia, the company determined that recovering its investment would be impossible and discontinued the project.」
The NIP-022 project was discontinued. The drug discovery pipeline includes both discontinued projects and the start of clinical development for new projects. - FY2021AdvancedAnnual report
「NTC-801, an antiarrhythmic drug, was selected for the Innovative Medical Seeds Practical Application Research Program operated by the Japan Agency for Medical Research and Development (AMED), and an investigator-initiated clinical trial was started at Osaka University, the joint research partner, in patients with hereditary bradyarrhythmia.」
NTC-801 advanced clinically through its selection for an AMED program and the start of an investigator-initiated clinical trial at Osaka University. - FY2018AdvancedAnnual report
「The Phase I clinical trial in Japan in healthy adults, which began in 2016, was completed in 2017. The company is currently formulating its future clinical development plans.」
The domestic Phase I clinical trial of NIP-022 was completed, while the joint research with 田辺三菱製薬 ended. New partnerships and research are being advanced, including joint research with 塩野義製薬 on a novel pain treatment. - FY2017First statedAnnual report
「For NIP-022, a platelet-increasing drug, a licensing agreement was signed with YAKULT HONSHA CO.,LTD. in October 2015. The two companies jointly advanced development of the drug and began a Phase I clinical trial in Japan in 2016 in healthy adults. In March 2017, a joint research agreement was signed with 田辺三菱製薬㈱ for a joint research program to discover novel autoimmune disease treatments.」
The company is advancing joint research and clinical development, including the Phase I clinical trial of NIP-022, the joint research agreement with 田辺三菱製薬 and the fungal infection treatment discovery program with 塩野義製薬.